Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.40 |
| ▸ | JUN | P05412 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | KCNQ3 | O43525 | 5/20 | 0.37 |
| ▸ | KCNQ2 | O43526 | 5/20 | 0.37 |
| ▸ | KCNQ5 | Q9NR82 | 5/20 | 0.37 |
| ▸ | KCNE1 | P15382 | 3/20 | 0.37 |
| ▸ | KCNQ1 | P51787 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19283609 | 0.89 | JUN (0.35) | NAPRTJUNNFKB1NFKB2RELA | |
| SCHEMBL13160131 | 0.77 | CA5A (0.44) | KCNJ1CA5AKDM4EALDH1A1ALOX15 | |
| SCHEMBL29131391 | 0.77 | KCNJ1 (0.39) | KCNJ1CA5AKDM4EALDH1A1ALOX15 | |
| SCHEMBL2175856 | 0.77 | KCNJ1 (0.39) | KCNJ1CA5AKDM4EALDH1A1ALOX15 | |
| SCHEMBL63857 | 0.77 | NAPRT (0.58) | NAPRTJUNNFKB1NFKB2RELA | |
| SCHEMBL6987829 | 0.77 | NAPRT (0.46) | NAPRTJUNNFKB1NFKB2RELA | |
| SCHEMBL3718941 | 0.75 | KCNJ1 (0.38) | KCNJ1CA5AKDM4EALDH1A1ALOX15 | |
| SCHEMBL19453610 | 0.75 | DGAT1 (0.37) | NAPRTJUNNFKB1NFKB2RELA | |
| SCHEMBL7993712 | 0.75 | CA5A (0.42) | KCNJ1CA5AKDM4EALDH1A1ALOX15 | |
| SCHEMBL1647572 | 0.75 | HDAC1 (0.56) | KCNJ1CA5AKDM4EALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3911640-B1 | PCSK9 INHIBITORS FOR USE IN THERAPY, ESPECIALLY THE TREATMENT OF CARDIOVASCULAR DISEASE | ASTRAZENECA AB (SE) | 2026-05-13 | — | — | EP | disclosed |
| US-12584120-B2 | PCSK9 inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2026-03-24 | — | — | US | disclosed |
| US-12552807-B2 | PCSK9 inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2026-02-17 | — | — | US | disclosed |
| US-12459927-B2 | Plasma kallikrein inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250333406-A1 | SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYSOWAY THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| EP-4630424-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | Third Harmonic Bio, Inc. (US) | 2025-10-15 | — | — | EP | disclosed |
| EP-4210694-B1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-10-15 | — | — | EP | disclosed |
| US-20250304597-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2025-10-02 | — | — | US | disclosed |
| EP-4615833-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING 2,5-SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | Nikang Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| US-12398130-B2 | Acid addition salts of piperazine derivatives | ASCENEURON SA (CH) | 2025-08-26 | — | — | US | disclosed |
| WO-2010089292-A1 | NOVEL SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS GAMMA SECRETASE MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010078408-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BIOGEN IDEC MA INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| EP-2167489-A2 | PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS | Sunesis Pharmaceuticals, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| EP-2167497-A2 | HETEROCYCLIC COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | Sunesis Pharmaceuticals, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2009134392-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| US-20090036419-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| WO-2009006404-A2 | HETEROCYCLIC COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009006389-A2 | PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| US-20090005359-A1 | Heterocyclic Compounds Useful as RAF Kinase Inhibitors | SUNESIS PHARMACEUTICALS, INC (US) | 2009-01-01 | — | — | US | disclosed |
| EP-0325131-A2 | Pyrimidine derivatives as performance stimulating agents | BAYER AG (DE) | 1989-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304597-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | HPGD, GCDH, HPGDS | NAPRT 948/4885JUN 3948/4885NFKB1 1754/4885 |
| US-20090036419-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | NAPRT 1334/4885JUN 863/4885NFKB1 1298/4885 |
| US-12552807-B2 | PCSK9 inhibitors and methods of use thereof | PCSK9, PCSK7, PCSK6 | NAPRT 2989/4885JUN 2244/4885NFKB1 2390/4885 |
| US-12584120-B2 | PCSK9 inhibitors and methods of use thereof | PCSK9, LDLR, PCSK7 | NAPRT 1834/4885JUN 2241/4885NFKB1 3806/4885 |
| US-12398130-B2 | Acid addition salts of piperazine derivatives | DNPEP, GAA, SLC30A5 | NAPRT 192/4885JUN 2911/4885NFKB1 1060/4885 |
| US-12459927-B2 | Plasma kallikrein inhibitors | KLKB1, SERPINE1, KLK5 | NAPRT 2685/4885JUN 1901/4885NFKB1 712/4885 |
| US-20090005359-A1 | Heterocyclic Compounds Useful as RAF Kinase Inhibitors | BRAF, RAF1, ARAF | NAPRT 919/4885JUN 544/4885NFKB1 1225/4885 |
| US-20250333406-A1 | SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | STOML2, ATP2A3, ATP2A1 | NAPRT 2906/4885JUN 4236/4885NFKB1 4253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.